499 related articles for article (PubMed ID: 32203305)
1. Cellular rewiring in lethal prostate cancer: the architect of drug resistance.
Carceles-Cordon M; Kelly WK; Gomella L; Knudsen KE; Rodriguez-Bravo V; Domingo-Domenech J
Nat Rev Urol; 2020 May; 17(5):292-307. PubMed ID: 32203305
[TBL] [Abstract][Full Text] [Related]
2. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
3. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
4. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
5. Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC).
Jonnalagadda B; Arockiasamy S; Krishnamoorthy S
Life Sci; 2020 Oct; 259():118208. PubMed ID: 32763294
[TBL] [Abstract][Full Text] [Related]
6. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.
Edwards J; Bartlett JM
BJU Int; 2005 Jun; 95(9):1320-6. PubMed ID: 15892825
[No Abstract] [Full Text] [Related]
7. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
Li P; Yang R; Gao WQ
Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
9. PI3K pathway in prostate cancer: All resistant roads lead to PI3K.
Park S; Kim YS; Kim DY; So I; Jeon JH
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):198-206. PubMed ID: 30300679
[TBL] [Abstract][Full Text] [Related]
10. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
Edlind MP; Hsieh AC
Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance and drug sequence in prostate cancer.
Buck SAJ; Koolen SLW; Mathijssen RHJ; de Wit R; van Soest RJ
Drug Resist Updat; 2021 May; 56():100761. PubMed ID: 33799049
[TBL] [Abstract][Full Text] [Related]
12. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
13. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
Mourkioti I; Polyzou A; Veroutis D; Theocharous G; Lagopati N; Gentile E; Stravokefalou V; Thanos DF; Havaki S; Kletsas D; Panaretakis T; Logothetis CJ; Stellas D; Petty R; Blandino G; Papaspyropoulos A; Gorgoulis VG
J Exp Clin Cancer Res; 2023 Jul; 42(1):187. PubMed ID: 37507762
[TBL] [Abstract][Full Text] [Related]
14. Androgen pathway resistance in prostate cancer and therapeutic implications.
Maughan BL; Antonarakis ES
Expert Opin Pharmacother; 2015; 16(10):1521-37. PubMed ID: 26067250
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.
Silberstein JL; Taylor MN; Antonarakis ES
Curr Urol Rep; 2016 Apr; 17(4):29. PubMed ID: 26902623
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
Uzzo RG; Haas NB; Crispen PL; Kolenko VM
Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A; Chatta G; Tang DG
Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
[TBL] [Abstract][Full Text] [Related]
20. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
